Overview

Inhaled GM-CSF for Respiratory Virus-Associated Severe Pneumonia

Status:
Withdrawn
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
This study will investigate the safety and efficacy of the administration of inhaled GM-CSF to patients with respiratory virus-associated pneumonia.
Phase:
Phase 1
Details
Lead Sponsor:
Milton S. Hershey Medical Center
Treatments:
Molgramostim
Sargramostim